Abstract:1169 Objectives The bradykinin B1 receptor (B1R), a G-protein coupled receptor, is overexpressed in several pathophysiological conditions including inflammation and cancer. B1R mediates nociception in the context of inflammation, and it is believed to contribute to tumourigenesis by promoting cell proliferation, invasion and angiogenesis. Previously, our lab reported the evaluation of several promising B1R-targeting peptides for cancer imaging. These peptides have high affinity to B1R and generate high-contrasted images of B1R-expressing tumour xenografts in mice. A significant number of potent B1R small molecule antagonists have been developed by pharmaceutical companies for the treatment of chronic pain, and could potentially be exploited for the design of B1R-targeting imaging agents. In this study, we investigated the use of an 18F-labeled small molecule (4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-[18F]fluoroethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide, 18F-Z02035) as an alternative to peptide-based B1R-imaging. Methods The non-radioactive Z02035 standard and its des-fluoroethyl precursor (4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-H-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide, Z02153) were synthesized via multi-step synthesis approach. The binding affinity of Z02035 for B1R was determined by in vitro competition binding assay using B1R-expressing cell membrane. 18F-Z02035 was prepared in two steps: (1) synthesis of 2-[18F]fluoroethyl tosylate by aliphatic nucleophilic substitution using 18F-fluoride and 1,2-bis(tosyloxy)ethane; and (2) coupling of 2-[18F]fluoroethyl tosylate with the precursor Z02153. PET imaging and biodistribution studies were performed at 1 h post-injection in mice bearing both B1R-positive HEK293T::hB1R and B1R-negative wild-type HEK293T tumours. Results The overall synthesis yield for the non-radioactive standard Z02035 was 1% (seven steps), and the yield for the precursor Z02153 was 47% (seven steps). Competition assays showed that Z02035 is a potent B1R binder with a Ki value of 0.93 ± 0.44 nM. By reacting Z02153 with 2-[18F]fluoroethyl tosylate, 18F-Z02035 was obtained in 6 ± 1% non-decay corrected yield with > 99% radiochemical purity and 0.9 ± 0.8 Ci/µmol specific activity. From PET images, 18F-Z02035 enabled visualization of the B1R-positive HEK293T::hB1R tumours with better contrast than the B1R-negative HEK293T tumours. In terms of clearance, 18F-Z02035 was excreted primarily through the hepatobiliary pathway. The average uptake in HEK293T::hB1R tumours (3.77 ± 0.79 %ID/g) was higher than in HEK293T tumours (2.11 ± 0.37 %ID/g). The tumour-to-muscle ratio for HEK293T::hB1R was 3.38 ±1.05. 18F-Z02035 exhibited slight defluorination in vivo as bone uptake was 4.63 ± 0.65 %ID/g. Conclusions We took a novel approach for targeting B1R expression by synthesizing an 18F-labeled small molecule. Although absolute uptake and overall contrast are lower than reported B1R tracers derived from peptide sequences, 18F-Z02035 was able to differentiate between B1R expressing and non-expressing tumour xenografts. Optimization to enhance tumour uptake/contrast and reduce in vivo defluorination is currently underway.

Synthesis and evaluation of an 18F-labeled boramino acid analog of aminosuberic acid for PET imaging of the antiporter system xC<sup/>

18F-Alanine Derivative Serves as an ASCT2 Marker for Cancer Imaging

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

A bis-boron boramino acid PET tracer for brain tumor diagnosis

Design of Novel 18 F-Labeled Amino Acid Tracers Using Sulfur 18 F-Fluoride Exchange Click Chemistry

Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography.

Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

A Bis‐Boron Amino Acid for Positron Emission Tomography and Boron Neutron Capture Therapy

Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve in Vivo Selectivity for Carbonic Anhydrase IX-Targeted PET Imaging.

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Synthesis and Evaluation of an 18F-Labeled Bradykinin B1 Receptor-Targeting Small Molecule for PET Imaging

[(18)F]fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

(18)F-Ambf3-mj9: a Novel Radiofluorinated Bombesin Derivative for Prostate Cancer Imaging.

Design, Synthesis and Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Aryl [18f]fluorosulfate Pet Tracers

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

Synthesis of 2-R 1 -2-(4-(2-fluoroethoxy)benzamido)acetate As Potential PET Imaging Agents

Synthesis and Biological Evaluation of a Radiolabeled PET (Positron Emission Tomography) Probe for Visualization of In Vivo α-Fucosidase Expression

Synthesis and application of 4-[(18)F]fluorobenzylamine: A versatile building block for the preparation of PET radiotracers

Preclinical study of an 18F-labeled glutamine derivative for cancer imaging.

Synthesis and evaluation of 18F-trifluoroborate derivatives of triphenylphosphonium for myocardial perfusion imaging

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.